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Abstract
Novel phosphorylated dihydroceramide (PDHC) lipids produced by the periodontal pathogen Porphyromonas gingivalis
include phosphoethanolamine (PE DHC) and phosphoglycerol dihydroceramides (PG DHC) lipids. These PDHC lipids
mediate cellular effects through Toll-like receptor 2 (TLR2) including promotion of IL-6 secretion from dendritic cells and
inhibition of osteoblast differentiation and function in vitro and in vivo. The PE DHC lipids also enhance (TLR2)-dependent
murine experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis. The unique non-mammalian
structures of these lipids allows for their specific quantification in bacteria and human tissues using multiple reaction
monitoring (MRM)-mass spectrometry (MS). Synthesis of these lipids by other common human bacteria and the presence of
these lipids in human tissues have not yet been determined. We now report that synthesis of these lipids can be attributed
to a small number of intestinal and oral organisms within the Bacteroides, Parabacteroides, Prevotella, Tannerella and
Porphyromonas genera. Additionally, the PDHCs are not only present in gingival tissues, but are also present in human
blood, vasculature tissues and brain. Finally, the distribution of these TLR2-activating lipids in human tissues varies with
both the tissue site and disease status of the tissue suggesting a role for PDHCs in human disease.
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Introduction
Porphyromonas gingivalis is a periodontal pathogen strongly
associated with development of destructive periodontal disease in
adults. We have recently characterized the structures of novel
phosphorylated dihydroceramide (PDHC) lipids produced by this
organism [1]. PDHCs include both low mass (LM) and high mass
(HM) forms of phosphoglycerol dihydroceramide (PG DHC) and
phosphoethanolamine dihydroceramide (PE DHC) lipids. These
lipids have unique non-mammalian structures [1] which allow for
their specific quantification in bacteria and human tissues using
multiple reaction monitoring (MRM)-mass spectrometry (MS).
These PDHC lipids are important because of their capacity to
engage Toll-like receptor 2 (TLR2) resulting in dendritic cell
secretion of IL-6 [2] and inhibition of osteoblast differentiation
and function [3]. In addition, we have shown that the PG DHC
lipids markedly stimulate proinflammatory secretory responses in
human gingival fibroblasts [1] and the PE DHC lipids enhance
murine experimental autoimmune encephalomyelitis (EAE), a
model for multiple sclerosis [2]. Others have shown that these
lipids promote apoptosis in HUVEC cells in culture through
activation of caspases 3, 6 and 9 [4]. In these previously reported
studies, the PDHC lipid classes were isolated only from P. gingivalis.
Little is known regarding the capacity of other common human
bacteria to produce these lipids and most importantly, whether
these lipids can be identified in human tissues distant from sites
normally colonized by these bacteria. Therefore, the purpose of
this investigation was to evaluate intestinal bacterial species as well
as other periodontal organisms for their capacity to produce
PDHCs and to examine blood and human tissue samples for the
presence of these novel TLR2-activating bacterial lipids.
Results
We analyzed lipid extracts derived from greater than 240
individual human isolates representing over 90 intestinal bacterial
species. Of the intestinal bacterial species evaluated, only
approximately 5% produced PDHCs. Furthermore, only intestinal
organisms of the Bacteroides, Parabacteroides or Prevotella genera
produced PDHCs and of these, most produced predominantly PE
DHC lipids (see Table S1 for the data set). Furthermore, the
predominant PE DHC lipids produced by these intestinal
organisms were usually the LM PE DHC form (see Figure 1 for
lipid structures and Figure 2A for recovery of these lipids in
intestinal and oral bacteria). Of the intestinal bacteria examined,
only Parabacteroides distasonis and Parabacteroides merdea produced the
PG DHC lipids, with P. distasonis producing primarily LM PG
DHCs and P. merdea producing primarily HM PG DHCs
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species known to be associated with inflammatory periodontal
disease in humans including Porphyromonas gingivalis, Tannerella
forsythia and Prevotella intermedia. Figure 2A shows that these species
vary in their capacity to produce either PE DHC or PG DHC
lipids and also vary in their production of the HM versus the LM
forms of these PDHCs. For example, the PDHC lipid constituents
produced by P. gingivalis are predominantly HM PE DHC lipids
whereas T. forsythia produces primarily LM PG DHC forms.
Though individual intestinal and oral organisms vary in their
capacity to produce specific PDHC lipids, combinations of these
organisms also have the potential to deposit unique mixtures of
PDHCs in human tissues and blood.
We next quantified bacterial PDHCs in human blood and tissue
samples (see Table S2 for the data set). We examined blood plasma
samples from periodontally healthy subjects, blood plasma samples
from subjects with generalized severe destructive periodontal disease
(chronic periodontitis), subgingival microbial plaque samples, and
normal human brain samples. For carotid endarterectomy samples,
we excised the patent segment of the common carotid artery (control
samples) from the grossly apparent atheroma of the carotid body and
quantified PDHCs within the lipid extracts of these paired carotid
samples.The patent carotidarterysamples showed no apparent gross
atheroma formation though these artery segments usually were
variably but significantly calcified within the artery wall.
We observed deposition of PDHCs in all of the human tissues
examined, but the distribution of PDHCs in these tissues showed
distinctive patterns. While the PDHCs derived directly from bacterial
samples tended to contain primarily either HM or LM PDHCs,
PDHC lipids in human tissue samples showed a mixture of HM and
LM forms suggesting a heterogenous bacterial source (see Figure 2B).
Nevertheless,tissue-associatedpatternsdescribedbelowsuggestthatit
may be possible to attribute a relatively specific distribution of
bacterial PDHCs to various human tissues in health and in disease.
PG DHC lipids (both the HM and LM forms) can exist with
three aliphatic chains (the substituted or ‘‘Sub’’ form) or can be de-
esterified to a lipid class with 2 aliphatic chains (the unsubstituted
or ‘‘Un’’ form) [1,5]. We next compared the de-esterification
status of the PG DHCs derived from bacteria with the PG DHCs
derived from human tissue samples. Of the intestinal and
periodontal organisms observed to produce PG DHCs, only P.
merdea produced a small amount of the UnPG DHC lipids (,10%
of total PDHC), whereas the remaining intestinal and oral bacteria
produced negligible amounts of UnPG DHC lipids (Figure 2A).
In contrast, human tissue samples revealed significant percent-
ages of both LM or HM UnPG DHC lipids (Figure 2B and
Figure 3). We next examined blood plasma samples from
periodontally healthy subjects and subjects with chronic periodon-
titis, and found that both revealed substantial percentages of both
LM and HM UnPG DHC lipids (Figure 2B and Figure 3). In
evaluating PG DHC de-esterification in atherosclerosis, we found
that the lipid extracts from atheroma artery segments revealed
significantly higher percentages of HM or LM UnPG DHC when
compared with the control artery extracts. This suggests that
atheroma formation is associated with greater de-esterification of
deposited SubPG DHC lipids.
Of note, the average total ion abundances of PDHC lipids per
microgram of total lipid extract were at least 33 times higher in the
control artery segments than the atheroma segments (see Table S3
for the data set). In fact, the highest levels of PDHC lipids in lipid
extracts from human tissue samples were observed in control
artery segments, not gingival tissue samples from periodontal
disease sites. The average levels of HM PE DHC and LM PE
DHC lipids were at least 44 times higher in the control artery
segments than the atheroma segments. This observation suggests
that the vascular system proximal to (or upstream from) the site of
atheroma formation is heavily contaminated with PDHC lipids.
Since the control artery segments demonstrated variable degrees of
Figure 1. Structures of bacterial phosphorylated dihydroceramides (PDHC) lipids. Each lipid species was quantified using multiple
reaction monitoring (MRM) mass spectrometry, via monitoring an MRM transition from the precursor lipid ion to the phosphorylated head group
fragment ion generated upon collision-induced dissociation. The structures of low and high mass PDHC lipids are based on previously published
reports [1,5]. Though PG DHC and PE DHC lipids normally exist in high, medium and low masses, we elected to quantify only the high and low mass
products because these vary most strongly between different bacterial species.
doi:10.1371/journal.pone.0016771.g001
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the possibility exists that the elevated bacterial lipid accumulation
is related to the process of mineralization in arterial walls without
grossly evident atheroma development. The reduced levels of
bacterial lipids in the atheroma lipid extracts compared to control
carotid lipid extracts is probably accounted for by the overwhelm-
ing accumulation of cholesterol and cholesterol esters that are
known to accompany atheroma formation. It is also possible that
substantial cholesterol accumulation during atheroma formation
could either prevent bacterial lipid accumulation in arterial walls
or cause release of bacterial lipids from artery walls. These
possibilities will be the subject of future research.
Lipid extracts of brain samples showed a mean percentage of
UnPG DHC lipids comparable to or higher than those observed in
carotid atheromas. In contrast, subgingival microbial plaque
samples taken from gingival crevices at periodontitis sites showed
only minimal levels of UnPG DHC. Subgingival plaque samples
are known to contain microbial organisms as well as desquamated
epithelial cells and inflammatory cells, and this combination
apparently possesses the capability to partially de-esterify PG
DHC lipids. These results suggest that metabolic conversion of the
SubPG DHC lipids to the UnPG DHC lipids, while not occurring
in the relevant bacteria, occurs both in blood and in some but not
all human tissues. The percentage of UnPG DHC lipids in blood
plasma samples compared with that in patent arterial samples and
paired atheroma samples further suggests that the UnPG DHC
lipids are not simply transported from blood to all tissues but may
undergo specific metabolic conversion within certain tissues.
Importantly, the biological properties of the SubPG DHC versus
the UnPG DHC lipids remain to be evaluated.
We next compared the distribution of PDHC lipids in gingival
tissue samples excised either from healthy/mildly inflamed or
destructive periodontal disease (periodontitis) sites. We also
evaluated blood plasma samples taken from periodontally healthy
Figure 2. Recovery of bacterial phosphorylated dihydroceramides in intestinal and oral bacteria, subgingival plaque samples,
blood plasma, atheroma and brain samples. Individual bacterial, blood and tissue samples were processed as described in the Methods section.
The ion abundances of high and low mass PDHC lipid classes were summed and the recovery of each lipid class is depicted as the percent of the total
ion abundance of the quantified PDHC lipids. Standard deviation bars are shown for lipid extracts from Bacteroides vulgatus (n=13), Prevotella copri
(n=2), Porphyromonas gingivalis (n=6), subgingival plaque (n=2), healthy/mildly inflamed gingival tissue (GT H+G, n=7), periodontitis gingival
tissue samples (GT Perio, n=6), control blood plasma (Blood Cont, n=8), blood plasma from patients with generalized severe periodontitis (Blood
Perio, n=6), carotid atheroma (Atheroma, n=11) and brain samples from deceased, neurologically-normal subjects (Brain Control, n=14). Recovery
of each lipid class is depicted as percent of the total PDHC ion recovery. Two-factor ANOVA indicated significant differences between categories of
human samples. Comparison of PDHC lipid distributions in healthy/mildly inflamed versus periodontitis gingival tissue samples revealed significant
differences for the percentage of HM SubPG DHC lipids, LM UnPG DHC lipids, LM PE DHC lipids.
doi:10.1371/journal.pone.0016771.g002
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factor ANOVA revealed significantly lower percentages of HM
and LM SubPG DHC lipids and significantly higher percentages
of HM and LM PE DHC lipids in periodontitis gingival tissue
samples versus healthy samples (Figure 2B). Similarly, blood
plasma samples demonstrated a significant increase in the
percentage of HM PE DHC lipids in periodontitis plasma versus
healthy plasma samples (though SubPG DHC percentages were
not lower in plasma samples from periodontitis patients).
For quantification of absolute PDHC lipid levels in control and
periodontitis gingival tissue samples, each tissue lipid extract was
supplemented with 1.5 mg of synthetic phospholipid internal
standard before analysis by MRM/MS. This analysis revealed
that lipid extracts of periodontitis tissue samples contained
significantly higher mean levels of HM PE DHC and LM PE
DHC lipids than that recovered in healthy gingival tissue samples
(p=0.0062 and p=0.0056, respectively, by one factor ANOVA,
see Table S2). However, all other PDHC lipids were not
significantly altered between periodontitis and healthy gingival
tissue samples. Therefore, we now show that shifts in the
deposition of specific bacterial lipids (PE DHCs) in gingival tissues
is directly correlated with expression of destructive periodontal
disease and that this specific increase in PE DHC is also reflected
in blood plasma levels. Given that we have demonstrated that PE
DHC can enhance murine autoimmunity [2], these results further
suggest both a pro-inflammatory and tissue destructive role for PE
DHC lipids and show that the absolute amount of PE DHC lipids
in gingival tissues could be an important bacterial marker for
expression of destructive periodontal disease in humans.
Overall, our findings indicate that human periodontal bacteria
and a small percentage of human intestinal bacterial produce
PDHC lipids, that these bacteria differ in the specific forms of
PDHCs they produce, that PDHCs accumulate in numerous
human tissues, and that the pattern of deposition varies not only
among the tissue sites involved but also with the state of
inflammation in those sites.
Discussion
We have recently demonstrated that unique bacterially-derived
lipids, termed PDHC lipids, promote cell activation through
TLR2 [2,3]. We now report that these bacterial lipids are
recovered in human tissue samples and blood, making it plausible
that PDHCs play a role in disease via acute and chronic activation
of the immune system. The varying percentages of PDHC lipid
species observed in either periodontal or intestinal bacterial species
suggests that a mixture of bacterial species normally account for
the overall blood and tissue deposition of these novel lipid classes.
The fact that bacterial lipids are prevalent in patent artery
segments suggests significant systemic exposure to these lipids.
This may occur through release of PDHCs upon bacterial death,
phagocytic engulfment of the PDHC-producing bacteria at their
sites of origin, and/or through intermittent bacteremias. Recent
studies have demonstrated that soluble bacterial peptidoglycan
originating from the intestinal microflora can be recovered in the
circulation and can subsequently prime neutrophils in bone
marrow [6,7]. Furthermore,
13C-labeled bacterial dihydrocera-
mides ingested by experimental animals were shown to be
distributed in skin, liver, skeletal muscle and brain, and a portion
of the bacterial dihydroceramides were metabolized in liver to
ceramides [8]. Therefore, our results demonstrating bacterial
PDHC lipids in human tissues and de-esterification of SubPG
DHC lipids in blood and tissues are consistent with these previous
reports. That bacterial PDHC lipids are known to engage TLR2
in promoting cell activation of dendritic cells, macrophages or
osteoblasts [2,3] and are prevalent even in patent artery segments,
raises the possibility that bacterial lipid deposition predisposes
major arteries to the development of atherosclerosis. Furthermore,
the relative predominance of PDHC lipids in control vessels
suggests that bacterial lipid accumulation in the vasculature occurs
before the majority of cholesterol and other mammalian lipids
accumulate within atheromas. Whether blood and tissue PDHCs
demonstrate transient variation in levels or fractional compositions
and whether such variations correlate with inflammatory or other
human diseases remains to be clarified.
We have demonstrated that PDHCs can promote autoimmune
disease in mice and that this process is dependent on expression of
TLR2 [2]. The role of the intestinal flora in both gastrointestinal
and systemic immune activation has received considerable
attention [9,10,11,12,13,14]. We postulate that the intestinal and
perhaps periodontal microbial production of PDHC lipids may
also play a role in both the systemic immune homeostasis of the
host and in disease mechanisms. For example, the relationship
between severity of periodontal disease and rheumatoid arthritis
[15,16,17,18,19] may relate to immune cell exposure to these
lipids either systemically or through the direct deposition of these
bacterial lipids in synovial sites.
Overall, our present findings provide a compelling rationale for
future studies investigating the relationship between bacterial
colonization of oral and intestinal sites, tissue deposition of PDHC
lipids and the capacity of these uniquely structured, TLR2-
activating lipids to promote human disease.
Materials and Methods
For research involving human participants, written informed
consent was obtained. The University of Connecticut Health
Figure 3. Recovery of bacterial phosphorylated dihydrocer-
amides in paired patent artery and atheroma samples. For each
carotid endarterectomy sample, the patent artery segment of the
proximal common carotid artery was excised from the grossly evident
atheroma located within the carotid sinus. The paired tissue samples
were separately extracted for lipids as described in the Methods. A
defined amount (approximately 3 mg of total lipids in 5 ml of HPLC
solvent) of each lipid extract was analyzed by MRM-MS and the recovery
of each lipid class is depicted as the percent of the total ion abundance
of the quantified PDHC lipids. The percentages of PDHC lipids are
depicted (means and standard errors) for five paired control and
atheroma lipid extracts. Significant differences between control versus
atheroma lipid extracts were shown only for the percentages of HM
UnPG DHC and LM UnPG DHC lipids (p=0.0144 and p=0.0258,
respectively, by paired t test). Though not shown, the mean
abundances of PDHC ions per mg of total lipid extract were at least
33 times higher for the control artery samples compared with the
atheroma samples.
doi:10.1371/journal.pone.0016771.g003
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human subject components of this study. Human atheroma,
blood and plaque samples were stored frozen (220uC) until the
time of lipid extraction. Human brain specimens were obtained as
postmortem samples from the Colorado Brain Bank, Denver, CO.
Intestinal bacterial samples that were previously stored frozen
were grown on blood agar plates after demonstrating purity of
bacterial isolates. The plates were scraped to recover the bacterial
colonies and were extracted using the phospholipid extraction
procedure of Bligh and Dyer [20] as modified by Garbus et al. [21].
Porphyromonas gingivalis (type strain, ATCC#33277), Tannerella
forsythia (generously provided by Dr. Sigmund Socransky) and
Prevotella intermedia (VPI 8944, generous gift of L.V. Moore) were
growninbrothcultureand afterpelletingbacteriabycentrifugation,
the bacterial pellets were stored frozen until processing. At the time
of lipid extraction, samples of bacterial pellets were removed and
extracted using the same phospholipid extraction procedure.
All tissue and blood samples were stored frozen until processing.
Gingival tissue, atheroma and brain samples were thawed and at
least 20 mg of tissue was minced and extracted for several days in
organic solvent according the method of Bligh and Dyer [20].
After drying organic solvent extracts under nitrogen, the lipid
extracts were reconstituted in hexane:isopropanol:water (HPLC
solvent, 6:8:0.75, v/v/v), vortexed and centrifuged. The resultant
supernatants were recovered, a sample of defined volume (5ml) was
dried and weighed, and a defined amount of each sample was
transferred to a clean glass vial either for further processing or for
MRM-MS analysis. For brain samples, 10 mg of each lipid extract
was fractionated by normal phase HPLC as previously described
[1] and the fractions expected to contain the PDHC lipids were
pooled and dried. Each brain lipid isolate was then reconstituted in
300 ml of HPLC solvent and 5 ml was analyzed by MRM-MS for
the bacterial lipids of interest. For each subgingival plaque sample,
50 mg of lipid extract was dissolved in 200 ml of HPLC solvent and
5 ml of each sample was analyzed by MRM-MS. For gingival
tissue samples, each gingival lipid sample (1 mg) was supplemented
with 50 mg of 1,2-di-(3,7,11,15-tetramethylhexadecanoyl)-sn-
glycero-3-phosphoserine and the characteristic 847 to 311 m/z
ion transition of this internal standard was used to correct for
bacterial lipid levels between gingival tissue lipid samples. Each
gingival lipid extract was then dissolved in 300 ml of HPLC solvent
and 5 ml of each sample was analyzed by MRM-MS. Citrated
blood samples, obtained by venipuncture from dental patients,
were diluted 2:1 in saline and subjected to Ficoll-Hypaque
centrifugation. The recovered plasma samples were stored frozen
until lipid extraction. For lipid extraction, the plasma samples were
thawed and 0.5 ml of each sample was extracted for lipids as
described above. The dried lipid samples were reconstituted in
300 ml of HPLC solvent and analyzed by MRM-MS.
Individual lipid samples were analyzed using a QTrap 4000
mass spectrometer (ABSciex). A standard volume of each lipid
sample (5 ml) was analyzed by flow injection and HPLC solvent
was run at a rate of 80 ml/min. Using previously purified lipid
preparations of each phosphorylated dihydroceramide class, the
instrument parameters were optimized for detection of each lipid
component based on gas phase transitions depicted in Figure 1.
The instrument parameters are listed in Table S4. Standard curves
were generated using serially diluted lipid standards of known
quantity and linearity of lipid quantification was observed
(regression coefficients .0.98). In addition, carryover of individual
lipid ion transitions into other monitored transitions was not
observed. Using the optimized instrument parameters, each lipid
extract from tissue, blood and bacterial samples was individually
analyzed.
Each lipid ion transition peak was electronically integrated and
the percentage abundance of each lipid class was calculated from
the integrated lipid ion transition peaks. For each category of tissue
or blood samples, all samples within a particular tissue or blood
category were analyzed during a single analysis session. One or
two-factor ANOVA, or the paired student t test was used to test for
significance differences between sample categories.
Supporting Information
Table S1 Ion abundances of bacterial phosphorylated dihydro-
ceramides recovered from each intestinal and oral bacterial isolate.
The individual bacterial samples were processed as described in
the Materials and Methods and individual lipid extracts were
evaluated by MRM-MS. Electronically integrated peaks depicted
here for each bacterial isolate were used to generate the summary
results shown in Figure 2A. Bacterial lipids that were not detected
are listed as ND.
(DOC)
Table S2 Ion abundances of bacterial phosphorylated dihydro-
ceramides recovered from individual lipid extracts of subgingival
plaque samples, and human gingival tissue, blood, atheroma and
brain samples. The individual tissue and blood specimens were
processed as described in the Materials and Methods and
individual lipid extracts were evaluated by MRM-MS. Electron-
ically integrated peaks depicted here were used to generate the
summary results shown in Figure 2B.
(DOC)
Table S3 Ion abundances of bacterial phosphorylated dihydrocer-
amides in lipid extracts of paired common carotid (control) and
carotid atheroma samples derived from human endarterectomy
samples. The individual tissue specimens were processed as described
in the Materials and Methods and individual lipid extracts were
evaluated by MRM-MS. Electronically integrated peaks depicted
here were used to generate the summary results shown in Figure 3.
(DOC)
Table S4 Mass spectrometric calibration parameters used to
quantify bacterial lipids in bacterial or human specimens. The
instrument parameters for the MRM-MS analysis are listed for the
4000QTrap Instrument (ABSciex). These parameters were defined
using highly purified preparations of each PDHC lipid class.
(DOC)
Author Contributions
Conceived and designed the experiments: FN XY BB JD SF EK JG WH
RC. Performed the experiments: FN XY BB JD SF EK JG WH RC.
Analyzed the data: FN XY BB JD SF EK RC. Contributed reagents/
materials/analysis tools: FN XY BB JD SF JG RC. Wrote the paper: FN
XY BB JD SF EK WH RC.
References
1. Nichols FC, Riep B, Mun J, Morton MD, Bojarski MT, et al. (2004) Structures
and biological activity of phosphorylated dihydroceramides of Porphyromonas
gingivalis. J Lipid Res 45: 2317–2330.
2. Nichols FC, Housley WJ, O’Conor CA, Manning T, Wu S, et al. (2009) Unique
lipidsfromacommonhumanbacteriumrepresentanewclassofToll-likereceptor
2 ligands capable of enhancing autoimmunity. Am J Pathol 175: 2430–2438.
Recovery of Bacterial Lipids in Human Tissues
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e167713. Wang YH, Jiang J, Zhu Q, Alanezi AZ, Clark RB, et al. (2010) Porphyromonas
gingivalis lipids inhibit osteoblastic differentiation and function. Infect Immun 78:
3726–3735.
4. Zahlten J, Riep B, Nichols FC, Walter C, Schmeck B, et al. (2007) Porphyromonas
gingivalis dihydroceramides induce apoptosis in endothelial cells. J Dent Res 86:
635–640.
5. Nichols FC, Rojanasomsith K (2006) Porphyromonas gingivalis lipids and diseased
dental tissues. Oral Microbiol Immunol 21: 84–92.
6. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, et al. (2010) Recognition of
peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity.
Nat Med 16: 228–231.
7. Philpott DJ, Girardin SE (2010) Gut microbes extend reach to systemic innate
immunity. Nat Med 16: 160–161.
8. Fukami H, Tachimoto H, Kishi M, Kaga T, Waki H, et al. (2010) Preparation of
13C-labeled ceramide by acetic acid bacteria and its incorporation in mice.
J Lipid Res.
9. Aumeunier A, Grela F, Ramadan A, Pham Van L, Bardel E, et al. (2010)
Systemic Toll-like receptor stimulation suppresses experimental allergic asthma
and autoimmune diabetes in NOD mice. PLoS One 5: e11484.
10. Mazmanian SK, Kasper DL (2006) The love-hate relationship between bacterial
polysaccharides and the host immune system. Nat Rev Immunol 6: 849–858.
11. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL (2005) An immunomod-
ulatory molecule of symbiotic bacteria directs maturation of the host immune
system. Cell 122: 107–118.
12. Round JL, Mazmanian SK (2009) The gut microbiota shapes intestinal immune
responses during health and disease. Nat Rev Immunol 9: 313–323.
13. Round JL, O’Connell RM, Mazmanian SK (2010) Coordination of tolerogenic
immune responses by the commensal microbiota. J Autoimmun 34: J220–225.
14. Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, et al. (2008) Innate
immunity and intestinal microbiota in the development of Type 1 diabetes.
Nature 455: 1109–1113.
15. Arkema EV, Karlson EW, Costenbader KH (2010) A Prospective Study of
Periodontal Disease and Risk of Rheumatoid Arthritis. J Rheumatol.
16. de Pablo P, Chapple IL, Buckley CD, Dietrich T (2009) Periodontitis in systemic
rheumatic diseases. Nat Rev Rheumatol 5: 218–224.
17. de Pablo P, Dietrich T, McAlindon TE (2008) Association of periodontal disease
and tooth loss with rheumatoid arthritis in the US population. J Rheumatol 35:
70–76.
18. Mikuls TR, Payne JB, Reinhardt RA, Thiele GM, Maziarz E, et al. (2008)
Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with
rheumatoid arthritis and periodontitis. Int Immunopharmacol.
19. Pischon N, Pischon T, Kroger J, Gulmez E, Kleber BM, et al. (2008) Association
among rheumatoid arthritis, oral hygiene, and periodontitis. J Periodontol 79:
979–986.
20. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and
purification. Can J Biochem Physiol 37: 911–917.
21. Garbus J, DeLuca HF, Loomas ME, Strong FM (1968) Rapid incorporation of
phosphate into mitochondrial lipids. J Biol Chem 238: 59–63.
Recovery of Bacterial Lipids in Human Tissues
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16771